{"ticker": {"uuid": "af88c2ee-4e37-4fa8-a649-1cdb4cc7dd56", "symbol": "SIGHT", "name": "GenSight Biologics S.A.", "exchange": "PAR", "country": "FR", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNYW5WSWQ4anFPa3hnSVh4Zk5aaDZTWnlEMTBWc1YzZWN3Z1pObVVTVkNZOWVoWGhnYm4wSWNUQ1c0ZklmaXM3ckJ0aVAyWDU2dVRQS28xblVrNTRUQUNsVEc1Qnp3MXFieXpVaFZGNzdZU2xBWXplckJjOTdmVUNFWFZYM3lqRUZDRXBBQi1JMVhTT29CNHBHa1YzMUQ0SXZmSm14LTBYVG83bmpCUmJjcDY5YVlxOXpFMDRIT1VJQnNQR0JVSFMycHlvQ1FOcWZBUElPZ3JfVFJBQQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-08T17:11:09+00:00", "published_display": "08 Jul 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GenSight Biologics Reports Cash Position and Revenue from Early Access Program as of March 31, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxNSFhCeUh6cTNwTVZLU21YYlR2YlhROWtIWVh6ajdsTDJRTFljMHAweTZiT3BXVkZSYlRBSlFuUlpERndIT2RKcUU3cF9pOGVQUzRNVU1taGk0UElOZnZadnpCdTBUODlVWnNhUHJIV2puak1CRm5wMUpWcnZwVDJ2RXczZ1ZpWTBkRDlxUGNKc1dNeVFZZjRZMW91MVBQR2s2UDd2alROMHB2emdLcENBS3p5azRJN0NaQllmdnVNSHV0WmMwVWEtS3ZYcGRFaTVtWHloSWpweGxuMXVCVG1FWS1VeGF1dXJuMXlN?oc=5", "source_name": "Business Wire", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GenSight Biologics Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ\u00ae in France", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxPY0hCeWpMT3ozUEtabDNjd08ydWxJdHc5YUZINkRmdnVCOEFPRGRFeHI4aHYxbURwUEtaVnl1MWhZSURROE1WdzMzV3NPeThzbzBfRVhiZEJKWG91UVdjY3dTaUk1QVJiRzlfU2dnSDdjQzJuTjJIQXdlYWlWZFlrNkFfMWlHOGpsNTliRE5Od3hKWFJvTFBFaHhIb2prdkZlYVFGN05OcFZSaDI1VENKb0tjamhTQmU5WV9sWFFOZzI3SjdpOTdBOXRNSWRJdEpmN01tZWVwV1o0U2hFcm9hWXk5RV9KSTg?oc=5", "source_name": "BioSpace", "published_at": "2025-12-22T08:00:00+00:00", "published_display": "22 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNYW5WSWQ4anFPa3hnSVh4Zk5aaDZTWnlEMTBWc1YzZWN3Z1pObVVTVkNZOWVoWGhnYm4wSWNUQ1c0ZklmaXM3ckJ0aVAyWDU2dVRQS28xblVrNTRUQUNsVEc1Qnp3MXFieXpVaFZGNzdZU2xBWXplckJjOTdmVUNFWFZYM3lqRUZDRXBBQi1JMVhTT29CNHBHa1YzMUQ0SXZmSm14LTBYVG83bmpCUmJjcDY5YVlxOXpFMDRIT1VJQnNQR0JVSFMycHlvQ1FOcWZBUElPZ3JfVFJBQQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-08T17:11:09+00:00", "published_display": "08 Jul 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GenSight Biologics Reports Cash Position and Revenue from Early Access Program as of March 31, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxNSFhCeUh6cTNwTVZLU21YYlR2YlhROWtIWVh6ajdsTDJRTFljMHAweTZiT3BXVkZSYlRBSlFuUlpERndIT2RKcUU3cF9pOGVQUzRNVU1taGk0UElOZnZadnpCdTBUODlVWnNhUHJIV2puak1CRm5wMUpWcnZwVDJ2RXczZ1ZpWTBkRDlxUGNKc1dNeVFZZjRZMW91MVBQR2s2UDd2alROMHB2emdLcENBS3p5azRJN0NaQllmdnVNSHV0WmMwVWEtS3ZYcGRFaTVtWHloSWpweGxuMXVCVG1FWS1VeGF1dXJuMXlN?oc=5", "source_name": "Business Wire", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GenSight Biologics Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ\u00ae in France", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxPY0hCeWpMT3ozUEtabDNjd08ydWxJdHc5YUZINkRmdnVCOEFPRGRFeHI4aHYxbURwUEtaVnl1MWhZSURROE1WdzMzV3NPeThzbzBfRVhiZEJKWG91UVdjY3dTaUk1QVJiRzlfU2dnSDdjQzJuTjJIQXdlYWlWZFlrNkFfMWlHOGpsNTliRE5Od3hKWFJvTFBFaHhIb2prdkZlYVFGN05OcFZSaDI1VENKb0tjamhTQmU5WV9sWFFOZzI3SjdpOTdBOXRNSWRJdEpmN01tZWVwV1o0U2hFcm9hWXk5RV9KSTg?oc=5", "source_name": "BioSpace", "published_at": "2025-12-22T08:00:00+00:00", "published_display": "22 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 78, "total_relevant": 3, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 3, "score": 50, "total": 3, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "liquidity", "primary_label": "Balance sheet", "confidence": 54, "events": [{"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "earnings", "label": "Earnings", "weight": 0.55, "count": 1}, {"event": "general", "label": "Market update", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 0.08, "latest_week": "2026-07-10", "one_week_move": -1.0, "four_week_move": 3.3, "twelve_week_move": 1.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.869548, "market_dynamics_buy_signal": false, "relative_strength": -26.465297, "fair_value_gap": -70.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 42.9176, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.0% over one week, +3.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 49, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Balance sheet", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "marketscreener.com", "count": 1}, {"label": "Business Wire", "count": 1}, {"label": "BioSpace", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 3}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Balance sheet", "count": 1}, {"label": "Earnings", "count": 1}, {"label": "Market update", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Balance sheet", "tone": "neutral", "text": "54/100 classification confidence."}, {"label": "Company focus", "value": "3", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-1.0% over one week, +3.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates"}], "updated_at": "2026-07-17T21:22:48.645031+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}